Alexion Pharmaceuticals, Inc.
NASDAQ: ALXN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ludwig Hantson
- Employees
- 3,837
- Headquarters
- Boston, United States
- IPO year
- 1996
- Website
- http://www.alexion.com
Loading ALXN…
Loading profile data…Frequently asked questions about ALXN
What does Alexion Pharmaceuticals, Inc. (ALXN) do?
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a diverse range of therapeutic solutions. The company's established product portfolio features ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic...
Where does ALXN trade?
Alexion Pharmaceuticals, Inc. (ALXN) trades on the NASDAQ Global Select.
What sector is ALXN in?
Alexion Pharmaceuticals, Inc. (ALXN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Alexion Pharmaceuticals, Inc.?
Ludwig Hantson is the chief executive officer of Alexion Pharmaceuticals, Inc. (ALXN).
Where is Alexion Pharmaceuticals, Inc. headquartered?
Alexion Pharmaceuticals, Inc. is headquartered in United States.
Does ALXN pay a dividend?
Alexion Pharmaceuticals, Inc. (ALXN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALXN go public?
Alexion Pharmaceuticals, Inc. (ALXN) completed its initial public offering in 1996.